Evaluation of Crestor® (Rosuvastatin) in Daily Practice
NCT ID: NCT00837083
Last Updated: 2009-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
602 participants
OBSERVATIONAL
2007-01-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.
NCT01982461
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
NCT00525824
Crestor Versus Placebo in Subjects With Heart Failure
NCT00206310
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
NCT00347217
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
NCT00688454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no treatment with any statin in the last 3 months
Exclusion Criteria
* active liver disease, severe renal insufficiency
* myopathy or predisposing risk factors for myopathy/ rhabdomyolysis
* woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matija Cevc, MD
Role: PRINCIPAL_INVESTIGATOR
University Medical Centre Ljubljana
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CRE 01/06
Identifier Type: -
Identifier Source: secondary_id
NIS-CSI-CRE-2006/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.